Phase II year
2016
(last award dollars: 2017)
Phase II Amount
$1,482,472
We have developed and completed a proof-of-principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to PCSK9 injection, and have identified a set of high affinity neutralizing antibodies which will be tested in animals for efficacy and potency.
Public Health Relevance Statement: Public Health Relevance: Therapeutic and diagnostic applications of monoclonal antibodies (mAbs) offer a way to target treatments to specific proteins. However, monoclonal antibodies have traditionally been made using hybridoma technologies which only access a small fraction of the immune system. Abeome has developed a novel method of antibody discovery using direct sorting of antigen- specific antibody producing cells. Thus, the immediate goal for this Phase 2 project is to test and improve Abeome's newly discovered antibodies that neutralize the PCSK9/LDLR interaction in animals to determine their efficacy and potency. Our ultimate goal is to develop an immuno- therapeutic for the treatment of hypercholesterolemia and to partner the technology with pharmaceutical/biotechnology companies.
NIH Spending Category: Atherosclerosis; Biotechnology; Cardiovascular; Digestive Diseases
Project Terms: Affinity; animal efficacy; Animals; Antibodies; Antibody Repertoire; Antibody-Producing Cells; Antigens; Biological Assay; Biotechnology; Clinical; Diagnostic; Escherichia coli; Evaluation; Goals; Hybridomas; hypercholesterolemia; Immune; Immune system; improved; Injection of therapeutic agent; Methods; Modality; Monoclonal Antibodies; mouse model; neutralizing antibody; novel; novel therapeutic intervention; Pharmacologic Substance; Phase; Proteins; public health relevance; response; Sorting - Cell Movement; Technology; Testing; Therapeutic; Transgenic Mice